The cortical neuritic pathology of Huntington's disease

We have studied the brains of 10 patients with clinically and pathologically defined Huntington's disease and graded the degree of striatal pathology according to the Vonsattel grading system. Sections from nine cerebral cortical areas (Brodmann areas 8. 10, 24, 33, 28, 38, 7, 39, 18), the cerebellum, hypothalamus, medulla and caudate nucleus were stained with antibodies to ubiquitin and ubiquitin C‐terminal hydrolase (PGP 9.5). Dystrophic neurites. immunoreactive with ubiquitin and PGP 9.5 were detected in all cortical areas. in layers 3, 5 and 6, of all brains studied. No dystrophic neurites were found in subcortical areas or cerebellum. Sections from cortical areas 8 and 24 from the two brains with the most and least ubiquitin‐immunoreactive neurites were stained with antibodies to β‐amyloid precursor protein, tau, glial fibrillary acidic protein, neurofilament protein, αB crystallin, GABA, cholecystokinin and somatostatin. The dystrophic neurites were found to also react with β‐amyloid precursor protein. Electron microscopy showed the abnormal neurites to contain granulo‐filamentous material. Granular deposits with a diameter of 40–100 nm were interspersed between randomly orientated ‘fuzzy’ or coated, straight or slightlv curved filaments measuring 10–15 nm in diameter. These structures have not been seen in control brain and differ from age‐related neuritic degeneration and neurites associated with amyloid. Immunohistochemically these structures most resemble CA 2/3 neurites seen in Lewy body disease, and, ultrastructurally, the intraneuronal filamentous inclusions in motor neuron disease. The areal density of these neurites was quantified in 20 microscopic fields in the superior frontal and anterior cingulate sections (Brodmann areas 8 and 24) and did not correlate with the Vonsattel grade, suggesting that they are an independent and possibly primary cortical pathology in Huntington's disease.

[1]  R. Mayer,et al.  αB crystallin expression in nonlenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease , 1992, The Journal of pathology.

[2]  D. Price,et al.  Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. S. Williams,et al.  Morphometric analysis of the prefrontal cortex in Huntington's disease , 1991, Neurology.

[4]  Anne M. Wang,et al.  Neuroaxonal Dystrophy Due to Lysosomal α-N-Acetylgalactosaminidase Deficiency , 1989 .

[5]  Paul W Goldberg,et al.  A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. , 1994, The New England journal of medicine.

[6]  B. O'neill,et al.  The adrenoleukomyeloneuropathy complex , 1981, Neurology.

[7]  R. Mayer,et al.  A filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunocytochemical localisation of ubiquitin , 1988, Neuroscience Letters.

[8]  D. Dickson,et al.  Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease , 1991, Neurology.

[9]  M. Cudkowicz,et al.  Degeneration of pyramidal projection neurons in Huntington's disease cortex , 1990, Annals of neurology.

[10]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[11]  Joseph B. Martin,et al.  Reply from Neil Kowall and colleagues , 1987, Trends in Neurosciences.

[12]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[13]  R. Lasek,et al.  Inhibition of proteolysis blocks anterograde-retrograde conversion of axonally transported vesicles , 1988, Brain Research.

[14]  M. Tabaton,et al.  Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: a pathological correlate of dementia? , 1993, Neuroscience Letters.

[15]  B Bacci,et al.  Amyloid precursor protein and ubiquitin immunoreactivity in dystrophic axons is not unique to Alzheimer's disease. , 1991, The American journal of pathology.

[16]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[17]  B. Sandok.  Dementia. A clinical approach. , 1972, Minnesota medicine.

[18]  E. Mancall,et al.  Development of neuropsychological deficits in Huntington's disease. , 1983, Archives of neurology.

[19]  D. Dickson,et al.  Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[20]  W. Martin,et al.  Cortical glucose metabolism in Huntington's disease , 1992, Neurology.

[21]  G. Graveland,et al.  Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. , 1985, Science.

[22]  J. Lowe,et al.  Ubiquitin carboxyl‐terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases , 1990, The Journal of pathology.

[23]  J. Vonsattel,et al.  Morphometric Demonstration of Atrophic Changes in the Cerebral Cortex, White Matter, and Neostriatum in Huntington's Disease , 1988, Journal of neuropathology and experimental neurology.

[24]  Yoichi Nakazato,et al.  New ubiquitin-positive intraneuronal inclusions in the extra-motor cortices in patients with amyotrophic lateral sclerosis , 1991, Neuroscience Letters.

[25]  R. Mayer,et al.  Ubiquitin in Neurodegenerative Diseases , 1993, Brain pathology.

[26]  J. B. Martin,et al.  Clinical and neuropathologic assessment of severity in Huntington's disease , 1988, Neurology.